Tokushima University / Educator and Researcher Directory --- Nakamura, Fumika

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study., Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024. (Summary) Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged ≥50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged ≥50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16530 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514 ● Search Scopus @ Elsevier (PMID): 38419514 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530 (DOI: 10.1111/jgh.16530, PubMed: 38419514)
2.	Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama : Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study., Journal of Gastroenterology and Hepatology, Vol.Online ahead of print., 2024. (Summary) The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged ≥ 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged ≥ 50 years is important for gallstone prevention. (Link to Publication Site) ● Publication site (DOI): 10.1111/jgh.16483 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880 ● Search Scopus @ Elsevier (PMID): 38212880 ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483 (DOI: 10.1111/jgh.16483, PubMed: 38212880)
3.	Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama : Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series., Clinical Journal of Gastroenterology, Vol.Online ahead of print., 2023. (Summary) Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-023-01849-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658 ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432 (DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus)
4.	Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, Shota Fujimoto, ma beibei, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama : Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice., Scientific Reports, Vol.13, No.1, 2899, 2023. (Summary) Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear. We first examined the expression of angiogenesis-related factors in inflamed colorectal tissue of UC patients using antibody array, and identified the 5 factors with highest expression, which included matrix metalloproteinase-8, urokinase-type plasminogen activator (uPA), angiostatin/plasminogen, hepatocyte growth factor and endoglin. Subsequent real-time PCR experiments using additional colorectal tissues revealed that uPA mRNA levels were significantly higher in inflamed tissues than in non-inflamed tissues, and significantly correlated with the severity of UC. Mirror section immunohistochemistry revealed that uPA was expressed in the neutrophils of inflamed colorectal tissues. We administered dextran sulfate sodium (DSS) in drinking water to uPA knockout (uPA) mice, and found that the disease activity index in uPA mice was marginally lower and the histological score in uPA mice was significantly lower than those in wild-type mice, suggesting the importance of uPA in colitis. When an uPA-selective inhibitor, UK122, was administered to DSS-treated C57BL6J mice, the disease activity index and histological score in those mice were significantly lower compared with control mice. Multiple cytokine/chemokine assay using colorectal tissues from uPA and UK122-treated mice revealed significantly lowered level of RANTES. In conclusion, uPA was highly expressed in neutrophils of the inflamed mucosa of UC patients, and the expression level correlated with the severity of UC. Genetic uPA deletion or pharmacological uPA blockade significantly ameliorated colitis in mice, concomitant with downregulation of RANTES. (Keyword) Animals / Mice / Urokinase-Type Plasminogen Activator / Colitis / Colitis, Ulcerative / Serine Proteases / Colorectal Neoplasms (Tokushima University Institutional Repository) ● Metadata: 118522 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-023-29824-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36806262 ● Search Scopus @ Elsevier (PMID): 36806262 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-023-29824-1 (Tokushima University Institutional Repository: 118522, DOI: 10.1038/s41598-023-29824-1, PubMed: 36806262)
5.	Fumika Nakamura, Yasushi Sato, Koichi Okamoto, Yasuteru Fujino, Yasuhiro Mitsui, kaizo kagemoto, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Naoki Muguruma, Tomoko Sonoda, Koichi Tsuneyama and Tetsuji Takayama : Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome., Journal of Gastroenterology, Vol.57, No.4, 286-299, 2022. (Summary) Although serrated polyposis syndrome (SPS) is associated with an increased colorectal cancer (CRC) risk, the carcinogenic mechanisms remain unknown. We investigated clinicopathological characteristics and genetic abnormalities in colorectal polyps and CRC to elucidate carcinogenic mechanisms in SPS. We retrospectively analyzed clinicopathological features of colorectal polyps in 44 SPS patients, and examined mutations of genes including APC, RAS, BRAF, and TP53, and microsatellite instability (MSI) in CRC tissues. Of the 44 patients, 25 (56%) fulfilled WHO criterion 1, 11 (25%) fulfilled criterion 2, and 8 (18%) fulfilled both. A total of 956 polyps were observed; 642 (67%) hyperplastic polyps (HP), 204 (21%) sessile serrated lesions (SSL), 10 (1%) traditional serrated adenoma (TSA), and 100 (11%) adenomas. The median numbers of polyps (/patient) were 10.5 (IQR 2.75-23) HPs, 4.0 (2.0-6.0) SSLs, 0 (0-0) TSA, and 1 (0-3.3) adenoma. SSL and HP located preferentially in the proximal and distal colon, respectively. Twenty-two CRCs were found in 18 patients. Based on the histological coexistence of SSL/TSA, BRAF mutation and MSI, 5 CRCs (26%) were classified as serrated-neoplasia pathway. Conversely, based on the coexistence of adenoma, APC/RAS and TP53 mutations, 11 CRCs (58%) were classified as adenoma-carcinoma pathway. The remaining three were unclassifiable. Most CRCs through adenoma-carcinoma pathway were located in the left-side colorectum and patients bearing those met criterion 2, characterized by many HP and advanced adenomas. Adenoma was a significant risk factor for CRC. Our results suggest that more than half of the CRCs, particularly those in the left-side colorectum, developed through the adenoma-carcinoma pathway in SPS patients. Adenoma was a risk factor for CRCs, suggesting its importance in colorectal carcinogenesis. (Keyword) Adenoma / Carcinoma / Colonic Polyps / Colorectal Neoplasms / Humans / Intestinal Polyposis / Microsatellite Instability / Mutation / Proto-Oncogene Proteins B-raf / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 117614 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-022-01858-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35194694 ● Search Scopus @ Elsevier (PMID): 35194694 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01858-8 (Tokushima University Institutional Repository: 117614, DOI: 10.1007/s00535-022-01858-8, PubMed: 35194694)
6.	Yasutsugu Shimohara, Yuji Urabe, Shiro Oka, Hisabe Takahashi, Atsushi Yamada, Hiro-o Matsushita, Bunichiro Kato, Hirotsugu Sakamoto, Joichiro Horii, Daisuke Watanabe, Hirotsugu Ega, Fumika Nakamura, Akiko Chino, Hironori Yamamoto, Tetsuji Takayama, Takayuki Matsumoto, Hideki Ishikawa and Shinji Tanaka : Clinicopathological characteristics of colorectal serrated polyposis syndrome (SPS): results of a multicenter study by the SPS Study Group in Japan., Journal of Gastroenterology, Vol.57, No.4, 300-308, 2022. (Summary) Serrated polyposis syndrome (SPS), a type of colorectal polyposis characterized by multiple serrated polyps, is associated with a high risk of colorectal carcinoma (CRC). This study aimed to clarify the clinicopathological characteristics of SPS in Japan. We investigated the clinicopathological characteristics of patients with SPS from the "Multicenter Study on Clinicopathological Characteristics of SPS (UMIN 000032138)" by the Colorectal Serrated Polyposis Syndrome (SPS) Study Group. In this study, patients were diagnosed with SPS based on the 2019 World Health Organization (WHO) SPS diagnostic criteria. Ninety-four patients were diagnosed with SPS in 10 institutions between January 2001 and December 2017. The mean number (± standard deviation [SD]) of resected lesions per patient was 11.3 ± 13.8. The mean age at diagnosis of SPS was 63.3 ± 11.6 years, and 58 patients (61.7%) were male. Eighty-seven (92.6%) and 16 (17.0%) patients satisfied WHO diagnostic criteria I and II, respectively. Nine patients (9.6%) satisfied both criteria I and II. Carcinoma (T1-T4) were observed in 21 patients (22.3%) and 24 lesions. Of the 21 patients with CRC, 19 (90.4%) satisfied diagnostic criterion I, 1 (4.8%) satisfied diagnostic criterion II, and 1 (4.8%) satisfied diagnostic criteria I and II. There was no notable difference in the prevalence of CRC among patients who met diagnostic criterion I, II, and both I and II. Patients with SPS have a high risk of CRC and should undergo regular surveillance colonoscopy. Raising awareness of this syndrome is crucial. (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-022-01859-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35201414 ● Search Scopus @ Elsevier (PMID): 35201414 ● Search Scopus @ Elsevier (DOI): 10.1007/s00535-022-01859-7 (DOI: 10.1007/s00535-022-01859-7, PubMed: 35201414)
7.	Yasuteru Fujino, Kumiko Tanaka, Fumika Nakamura, Yoshifumi Kida, Akihiro Hirao, Yasuyuki Okada, Masanori Takehara, Akira Fukuya, Yoshimi Bando and Tetsuji Takayama : A CASE OF MULTIPLE COLONIC ULCERS CAUSED BY RHEUMATOID VASCULITIS, Gastroenterological Endoscopy, Vol.63, No.7, 1358-1364, 2021. (Keyword) リウマトイド血管炎 / 大腸潰瘍 (Link to Publication Site) ● Publication site (DOI): 10.11280/gee.63.1358 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390007282525435264 ● Search Scopus @ Elsevier (DOI): 10.11280/gee.63.1358 (DOI: 10.11280/gee.63.1358, CiNii: 1390007282525435264)
8.	Jun Okazaki, Toshihito Tanahashi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, beibei ma, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama : MicroRNA-296-5p Promotes Cell Invasion and Drug Resistance by Targeting Bcl2-Related Ovarian Killer, Leading to a Poor Prognosis in Pancreatic Cancer., Digestion, Vol.101, No.6, 794-806, 2020. (Summary) Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion, early metastasis, and resistance to chemotherapy, leading to a poor prognosis. To clarify the molecular mechanism of these malignant characteristics, we performed a genome-wide microRNA (miRNA) array analysis utilizing micro-cancer tissues from patients with unresectable PDAC (stage IV), obtained by endoscopic ultrasound-fine needle aspiration (EUS-FNA). The expression profiles of 2,042 miRNAs were determined using micro-cancer tissues from 13 patients with unresectable PDAC obtained by EUS-FNA. The relationship between individual miRNA levels and overall survival (OS) was analyzed. Possible target genes for miRNAs were bioinformatically analyzed using the online database miRDB. Pancreatic cancer cell lines PANC-1, MIA PaCa-2, and PK-8 were transfected with miRNA mimic or small interfering RNA, and cell invasion, epithelial-mesenchymal transition (EMT), and apoptosis markers were examined. miRNA and mRNA expressions were examined by quantitative polymerase chain reaction. Of 2,042 miRNAs, the 10 that exhibited the lowest correlation coefficient (p 0.005) between miRNA expression level and OS among the patients were identified. The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005). Bioinformative target gene analysis and transfection experiments with miRNA mimics showed that Bcl2-related ovarian killer (BOK), a pro-apoptotic gene, is a target for miR296-5p in pancreatic cancer cells; transfection of miR-296-5p mimic into PANC-1, MIA PaCa-2, and PK-8 cells resulted in significant suppression of BOK mRNA and protein expression. These transfectants showed significantly higher invasion capability compared with control cells, and knock down of BOK in pancreatic cancer cells similarly enhanced invasion capability. Transfectants of miR-296-5p mimic also exhibited aberrant expression of EMT markers, including vimentin and N-cadherin. Moreover, these transfectants showed a significantly lower apoptosis rate in response to 5-fluorouracil and gemcitabine with a decrease of BOK expression, suggesting a role of miR-296-5p in drug resistance. These results suggest that miR-296-5p is a useful biomarker for a poor prognosis in patients with PDAC, and that the miR-296-5p/BOK signaling axis plays an important role in cell invasion, drug resistance, and EMT in PDACs. (Tokushima University Institutional Repository) ● Metadata: 114153 (Link to Publication Site) ● Publication site (DOI): 10.1159/000503225 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31563901 ● Summary page in Scopus @ Elsevier: 2-s2.0-85072925180 (Tokushima University Institutional Repository: 114153, DOI: 10.1159/000503225, PubMed: 31563901, Elsevier: Scopus)
9.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE) との関連性についての検討, Shikoku Acta Medica, Vol.76, No.3-4, 173-178, 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050004953486029824 (CiNii: 1050004953486029824)
10.	Masanori Takehara, Yasushi Sato, Tetsuo Kimura, Kazuyoshi Noda, Hiroshi Miyamoto, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Hironori Wada, Yoshimi Bando, Tetsuya Ikemoto, Mitsuo Shimada, Naoki Muguruma and Tetsuji Takayama : Cancer-associated Adipocytes Promote Pancreatic Cancer Progression Through SAA1 Expression, Cancer Science, Vol.111, No.8, 2883-2894, 2020. (Summary) Although pancreatic cancer often invades into peripancreatic adipose tissue, little is known about the cancer-adipocyte interaction. We first investigated the ability of adipocytes to de-differentiate to cancer-associated adipocytes (CAAs) by co-culturing with pancreatic cancer cells. We then examined the effects of CAA-conditioned media (CAA-CM) on the malignant characteristics of cancer cells, the mechanism underlying those effects, and their clinical relevance in pancreatic cancer. When 3T3-L1 adipocytes were co-cultured with pancreatic cancer cells (PANC-1) using Transwell system, adipocytes lost their lipid droplets and morphologically changed to fibroblast-like cells (CAA). Adipocyte-specific marker mRNA levels significantly decreased but those of fibroblast-specific markers appeared, characteristic findings of CAA, as revealed by real-time PCR. When PANC-1 cells were cultured with CAA-CM, significantly higher migration/invasion capability, chemoresistance, and epithelial-mesenchymal transition (EMT) properties were observed compared with control cells. To investigate the mechanism underlying these effects, we performed microarray analysis of PANC-1 cells cultured with CAA-CM, and found 78.5-fold higher expression of SAA1 compared with control cells. When SAA1 gene in PANC-1 cells was knocked down with SAA1 siRNA, migration/invasion capability, chemoresistance, and EMT properties were significantly attenuated compared with control cells. Immunohistochemical analysis on human pancreatic cancer tissues revealed positive SAA1 expression in 46/61 (75.4%). Overall survival in the SAA1-positive group was significantly shorter than in the SAA1-negative group (p=0.013). In conclusion, we demonstrated that pancreatic cancer cells induced de-differentiation in adipocytes toward CAA, and CAA promoted malignant characteristics of pancreatic cancer via SAA1 expression, suggesting that SAA1 is a novel therapeutic target in pancreatic cancer. (Tokushima University Institutional Repository) ● Metadata: 115328 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.14527 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32535957 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087562532 (Tokushima University Institutional Repository: 115328, DOI: 10.1111/cas.14527, PubMed: 32535957, Elsevier: Scopus)
11.	Hironori Tanaka, Koichi Okamoto, Yasushi Sato, Takahiro Tanaka, Tetsu Tomonari, Fumika Nakamura, Yasuteru Fujino, Yasuhiro Mitsui, Hiroshi Miyamoto, Naoki Muguruma, Akinori Morita, Hitoshi Ikushima and Tetsuji Takayama : Synergistic anti-tumor activity of miriplatin and radiation through PUMA-mediated apoptosis in hepatocellular carcinoma., Journal of Gastroenterology, Vol.55, No.11, 1072-1086, 2020. (Summary) The prognosis for patients with unresectable advanced hepatocellular carcinoma (HCC) is poor. Miriplatin is a hydrophobic platinum compound that has a long retention time in lesions after transarterial chemoembolization (TACE). We investigated anti-tumor activity of miriplatin combined with irradiation on HCC cells, and its underlying mechanism of apoptosis. We also analyzed the effectiveness of miriplatin-TACE and radiotherapy for locally advanced HCC. Human HCC cell lines HepG2 and HuH-7 were treated with DPC (active form of miriplatin) and radiation, and synergy was evaluated using a combination index (CI). Apoptosis-related proteins and cell cycles were analyzed by western blotting and flowcytometry. We retrospectively analyzed treatment outcomes in 10 unresectable HCC patients with vascular/bile duct invasion treated with miriplatin-TACE and radiotherapy. DPC or X-ray irradiation decreased cell viability dose-dependently. DPC plus irradiation decreased cell viability synergistically in both cell lines (CI < 1, respectively). Cleaved PARP expression was induced much more strongly by DPC plus irradiation than by each treatment alone. Expression of p53 up-regulated modulator of apoptosis (PUMA) was significantly induced by the combination, and knockdown of PUMA with siRNA significantly decreased apoptosis in both cell lines. DPC plus irradiation caused sub-G1, G2/M, and S phase cell arrest in those cells. The combination of miriplatin-TACE and radiotherapy showed a high response rate for patients with locally advanced HCC despite small number of patients. Miriplatin plus irradiation had synergistic anti-tumor activity on HCC cells through PUMA-mediated apoptosis and cell cycle arrest. This combination may possibly be effective in treating locally advanced HCC. (Tokushima University Institutional Repository) ● Metadata: 115325 (Link to Publication Site) ● Publication site (DOI): 10.1007/s00535-020-01705-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32666201 ● Summary page in Scopus @ Elsevier: 2-s2.0-85087895196 (Tokushima University Institutional Repository: 115325, DOI: 10.1007/s00535-020-01705-8, PubMed: 32666201, Elsevier: Scopus)
12.	Yoshihiko Miyamoto, Naoki Muguruma, Shota Fujimoto, Yasuyuki Okada, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Tadahiko Nakagawa, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : Epidermal growth factor receptortargeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models., Cancer Science, Vol.110, No.6, 1921-1930, 2019. (Summary) To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed. Moreover, it is also important to establish a new modality to evaluate viable tumor volume in primary lesions of colorectal cancer (CRC) during chemotherapy. Therefore, we carried out molecular imaging of colorectal tumors targeting epidermal growth factor receptor (EGFR), which is highly expressed on tumor cells, for evaluating chemotherapeutic efficacy and for endoscopic detection of colorectal adenomas. We first attempted to image five CRC cell lines with various levels of EGFR expression using an Alexa Fluor-labeled anti-EGFR monoclonal antibody (AF-EGFR-Ab). A strong fluorescence signal was observed in the cells depending on the level of EGFR expression. When nude mice xenografted with LIM1215 CRC cells, which highly express EGFR, were i.v. injected with AF-EGFR-Ab, a strong fluorescence signal appeared in the tumor with a high signal to noise ratio, peaking at 48 hours after injection and then gradually decreasing, as shown using an IVIS Spectrum system. When the xenografted mice were treated with 5-fluorouracil, fluorescence intensity in the tumor decreased in proportion to the viable tumor cell volume. Moreover, when the colorectum of azoxymethane-treated rats was observed using a thin fluorescent endoscope with AF-EGFR-Ab, all 10 small colorectal adenomas (3 mm) were detected with a clear fluorescence signal. These preliminary results of animal experiments suggest that EGFR-targeted fluorescent molecular imaging may be useful for quantitatively evaluating cell viability in CRC during chemotherapy, and also for detecting small adenomas using a fluorescent endoscope. (Keyword) Animals / Antineoplastic Agents / Azoxymethane / Cell Line, Tumor / Cell Survival / Colorectal Neoplasms / ErbB Receptors / female / Fluorouracil / HT29 Cells / Humans / male / Mice, Inbred BALB C / Mice, Nude / Molecular Targeted Therapy / Rats, Inbred F344 / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 113790 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.14020 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30973663 ● Summary page in Scopus @ Elsevier: 2-s2.0-85066789077 (Tokushima University Institutional Repository: 113790, DOI: 10.1111/cas.14020, PubMed: 30973663, Elsevier: Scopus)
13.	Hiroshi Miyamoto, Kumiko Tanaka, Fumika Nakamura, Takahiro Ikeda, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Yoshimi Bando and Tetsuji Takayama : Massive hemobilia following plastic stent removal in common bile duct cancer associated with primary sclerosing cholangitis (with video)., Clinical Journal of Gastroenterology, Vol.12, No.1, 2019. (Summary) Hemobilia is defined as bleeding into the biliary tract. Herein, we report a very rare case of massive hemobilia following plastic stent (PS) removal in common bile duct (CBD) cancer. A 72-year-old man with primary sclerosing cholangitis had undergone repeated insertion of a PS into the CBD. Biliary tract biopsy was performed based on suspicion of combined CBD cancer. Biopsy revealed poorly differentiated adenocarcinoma of the CBD. One month after the biliary tract biopsy, he was admitted for acute cholangitis, and endoscopic retrograde cholangiography was performed for the exchange of the PS. When one of the two biliary PSs was removed, spurting bleeding from the major papilla began abruptly. The massive bleeding caused the patient to be in a pre-shock state. A retrieval balloon catheter was compressed against the papilla for hemostasis. Although he was treated conservatively, the patient developed a bloody discharge. Upper gastrointestinal endoscopy revealed that the pulsatile bleeding beside the PSs started immediately after the removal of the coagula. Emergent contrast-enhanced computed tomography showed right hepatic artery aneurysm across the CBD. Therefore, transarterial embolization was performed. The patient's post-therapeutic course was uneventful. He received chemotherapy, but died about a half year after hemobilia occurred. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-018-0888-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30056613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85050721343 (DOI: 10.1007/s12328-018-0888-7, PubMed: 30056613, Elsevier: Scopus)
14.	Yuri Matsumoto, Hiroshi Miyamoto, Akira Fukuya, Fumika Nakamura, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masahiro Sogabe, Naoki Muguruma, Mitsuo Shimada, Yoshimi Bando and Tetsuji Takayama : Hemosuccus pancreaticus caused by a mucinous cystic neoplasm of the pancreas., Clinical Journal of Gastroenterology, Vol.10, No.2, 185-190, 2017. (Summary) Hemosuccus pancreaticus is a gastrointestinal hemorrhage through the main pancreatic duct. Here, we report a rare case of hemosuccus pancreaticus due to a mucinous cystic neoplasm of the pancreas. A 62-year-old woman who had been followed for a branch duct intraductal papillary mucinous neoplasm visited our emergency room due to severe abdominal pain and bloody discharge. Computed tomography revealed that the pancreatic cyst increased the tension of the wall and a high-density area indicative of bleeding into the cyst was observed. Endoscopy showed opening of and hemorrhaging from the papilla of Vater. The patient was diagnosed with hemosuccus pancreaticus caused by hemorrhaging into the cyst from the branch duct intraductal papillary mucinous neoplasm. Based on this diagnosis, elective distal pancreatectomy was performed. The histopathological diagnosis was a mucinous cystic neoplasm with intermediate-grade dysplasia based upon the pathological findings that fibrous ovarian-type stroma existed abundantly and the stroma cells were positive for progesterone receptor and inhibin. Hemosuccus pancreaticus caused by a mucinous cystic neoplasm is extremely rare and there has been only one case reported to date. In conclusion, it should be recognized that pancreatic cystic neoplasms including mucinous cystic neoplasms may cause hemosuccus pancreaticus. (Keyword) Ampulla of Vater / female / Gastrointestinal Hemorrhage / Humans / magnetic resonance imaging / Middle Aged / Neoplasms, Cystic, Mucinous, and Serous / Pancreatic Cyst / Pancreatic Ducts / Pancreatic Neoplasms / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1007/s12328-016-0711-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28054178 ● Summary page in Scopus @ Elsevier: 2-s2.0-85008158342 (DOI: 10.1007/s12328-016-0711-2, PubMed: 28054178, Elsevier: Scopus)
15.	Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Fumika Nakamura, Yasuyuki Okada, Tetsuo Kimura, Hiroshi Miyamoto and Tetsuji Takayama : Endoscopic submucosal dissection through a gastrostomy for early gastric cancer in patients with pharyngeal stenosis., Gastrointestinal Endoscopy, Vol.79, No.2, 206-207, 2014. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.gie.2013.09.018 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24129250 ● Summary page in Scopus @ Elsevier: 2-s2.0-84892564534 (DOI: 10.1016/j.gie.2013.09.018, PubMed: 24129250, Elsevier: Scopus)

Review, Commentary:

1.	Yasushi Sato, Koichi Okamoto, Tomoyuki Kawaguchi, Fumika Nakamura, Hiroshi Miyamoto and Tetsuji Takayama : Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives., Biomedicines, Vol.10, No.7, 1614, Jul. 2022. (Summary) Neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) has been recognized as an effective therapeutic option because it is expected to improve the curative resection rate by reducing the tumor size and preventing recurrence of micrometastases. However, for patients resistant to NAC, not only will operation timing be delayed, but they will also suffer from side effects. Thus, it is crucial to develop a comprehensive strategy and select patients sensitive to NAC. However, the therapeutic effect of NAC is unpredictable due to tumor heterogeneity and a lack of predictive biomarkers for guiding the choice of optimal preoperative treatment in clinical practice. This article summarizes the related research progress on predictive biomarkers of NAC for gastric cancer. Among the many investigated biomarkers, metabolic enzymes for cytotoxic agents, nucleotide excision repair, and microsatellite instability, have shown promising results and should be assessed in prospective clinical trials. Noninvasive liquid biopsy detection, including miRNA and exosome detection, is also a promising strategy. (Tokushima University Institutional Repository) ● Metadata: 117415 (Link to Publication Site) ● Publication site (DOI): 10.3390/biomedicines10071614 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35884916 ● Search Scopus @ Elsevier (PMID): 35884916 ● Search Scopus @ Elsevier (DOI): 10.3390/biomedicines10071614 (Tokushima University Institutional Repository: 117415, DOI: 10.3390/biomedicines10071614, PubMed: 35884916)

Proceeding of International Conference:

1.	Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota fujimoto, Tadahiko Nakagawa, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Sogabe, Koichi Tsuneyama and Tetsuji Takayama : Thepapeutic strategy of Ulcerative Colitis targeting Urokinase-type Plasminogen Activator., DDW2023, May 2023.
2.	Tetsuji Takayama, Yoshifumi Kida, Toshiya Okahisa, Yasushi Sato, Masahiro Bando, shota Fujimoto, Tomoyuki Kawaguchi, Fumika Nakamura, Koichi Okamoto, Hiroshi Miyamoto, Koichi Tsuneyama and Masahiro Sogabe : The relevance of urokinase-type plasminogen activator in pathogenesis of ulcerative colitis., WCOG2022 (World Congress of Gastroenterology), Dubai, Dec. 2022.
3.	Yasutsugu Shimohata, Yuji Urabe, Shiro Oka, Takashi Hisabe, Atsushi Yamada, Hiro-O Matsushita, Hirotsugu Sakamoto, Joichiro Horii, Daisuke Watanabe, Hirotsugu Eda, Fumika Nakamura, Hironori Yamamoto, Tetsuji Takayama, Takayuki Matsumoto, Shinji Tanaka and Hideki Ishikawa : Clinicopathological Characteristics of Serrated Polyposis Syndrome: Results of a Multicenter Study by the Colorectal Serrated Polyposis Syndrome (SPS) Study Group in Japan., Digestive Disease Week2021, May 2021.
4.	Yasushi Sato, Kumiko Tanaka, Ishikawa Hideki, Satoshi Teramae, Fumika Nakamura, Yasuhiro Mitsui, Kagemoto Kaizo, Hiroshi Miyamoto, Koichi Okamoto, Naoki Muguruma, Ohmiya Naoki, Mutoh Michihiro and Tetsuji Takayama : Small- intestinal involvement in familial adenomatous polyposis: characteristics and genotype- phenotype correlation from a Japanese cohort study, DDW, May 2020.
5.	Naoki Muguruma, Daisaku Fujimot, Tomoyuki Kawaguchi, Kaizoh Kagemoto, Satoshi Teramae, Yoshifumi Kida, Hironori Wada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Toshihito Tanahashi, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : Linked Color Imaging Improves Detection Rate of Sessile Serrated Adenoma/Polyp in the Colon: A Prospective Randomized Controlled Trial., UEG Week 2019, Barcelona, Oct. 2019.
6.	Shinji Kitamura, Mototsugu Kato, Kenro Kawada, Masanori Takehara, Kaizo Kagemoto, Fumika Nakamura, Hironori Wada, Naoki Muguruma, Osamu Dohi, Shoko Ono, Hideki Ishikawa and Tetsuji Takayama : Linked Color Imaging for the Detection of Gastric Neoplasm in High Risk Patients: A Prospective Multicenter Randomized Controlled Trial (LCI-FIND Trial)., UEG Week2019, Barcelona, Oct. 2019.
7.	Hironori Tanaka, Tetsu Tomonari, Takahiro Tanaka, Akihiro Hirao, Fumika Nakamura, Kumiko Tanaka, Koichi Okamoto, Yasushi Sato, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Therapeutic efficacy of chemoradiotherapy with Miriplatin for hepatocellular carcinoma., digestive disease week2019, San Diego, May 2019.
8.	Jinsei Miyoshi, Noriaki Murayama, Kumiko Tanaka, Takahiro Tanaka, Fumika Nakamura, Yasuteru Fujino, Keiichiro Matsumura, Miwako Kagawa, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Development of a Novel Mirna-Based Signature to Predict Invasion and Metastasis in Rectal Neuroendocrine Tumors., digestive disease week2019, Vol.156, No.6, 133, San Diego, May 2019. (Link to Publication Site) ● Publication site (DOI): 10.1016/S0016-5085(19)37123-9 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/S0016-5085(19)37123-9 (DOI: 10.1016/S0016-5085(19)37123-9)
9.	Jun Okazaki, Toshihito Tanahasi, Yasushi Sato, Jinsei Miyoshi, Tadahiko Nakagawa, Tetsuo Kimura, Hiroshi Miyamoto, Yasuteru Fujino, Fumika Nakamura, Masanori Takehara, Masahiro Bando, Shinji Kitamura, Koichi Okamoto, Naoki Muguruma, Masahiro Sogabe and Tetsuji Takayama : Interaction Between Pancreatic Cancer Cells and Adipocytes Promote Pancreatic Cancer Progression Through Overexpression of Saa1., digestive disease week2019, San Diego, May 2019.
10.	Tetsuji Takayama, Toshihito Tanahashi, Koichi Okamoto, Shota Fujimoto, Tadahiko Nakagawa, Kaizoh Kagemoto, Yasuyuki Okada, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Naoki Muguruma : S100P as a novel hypomethylation target in Sessile Serrated Adenoma(SSA/P)-cancer sequence: A genome-wide DNA methylation array analysis., UEG Week2018, Wien, Oct. 2018.
11.	Fumika Nakamura, Koichi Okamoto, Kumiko Tanaka, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Clinicopathological Analyses of Colorectal Polyps and Cancers in Serrated Polyposis Syndrome., DIgestive Disease Week2018, Washington, D.C., Jun. 2018.
12.	Daisaku Fujimoto, Kaizo Kagemoto, Yasuyuki Okada, Hironori Tanaka, Satoshi Teramae, Akihiro Hirao, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Usefulness of Linked Color Imaging System in Endoscopic Diagnosis of Sessile Serrated Adenoma/Polyp: A Novel Image Enhanced Technique., Digestive Disease Week2017, Chicago, May 2017.

Proceeding of Domestic Conference:

1.	reiko yokoyama, Fumika Nakamura, shota fujimoto, Takanori Kashihara, Masahiro Sogabe, Yasushi Sato and Tetsuji Takayama : 直腸原発悪性黒色腫に対する免疫チェックポイント阻害剤の有効性と免疫関連副作用の関連性., 第20回日本消化管学会総会学術集会, Feb. 2024.
2.	Koichi Okamoto, Motoko Sei, shota fujimoto, ta mitsuhashi, takanori yoshimoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的および分子生物学的解析, 第10回消化管ポリポーシス研究会, Jan. 2024.
3.	Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasuteru Fujino, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto and Tetsuji Takayama : 直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義., 第 61 回日本癌治療学会学術集会, Oct. 2023.
4.	Sayaka Ogimoto, Koichi Okamoto, Akira Takahashi, shota Fujimoto, Takanori Yoshimoto, Takeshi Mitsuhashi, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : 内視鏡による積極的大腸ポリープ摘除術を施行しているリンチ症候群の一例., 第5回がんゲノム医療時代におけるLynch症候群研究会学術集会, Aug. 2023.
5.	Koichi Okamoto, Fumika Nakamura and Tetsuji Takayama : Serrated polyposis syndromeに合併した左側および右側大腸腺腫の臨床病理学的特徴., 第109回日本消化器病学会総会, Apr. 2023.
6.	Hiroyuki Ueda, Tomoyuki Kawaguchi, Hironori Wada, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Yasushi Sato and Tetsuji Takayama : 右側大腸癌における TIMP1 の予後不良因子としての意義:右側及び左側大腸癌を比較して., 第19回日本消化管学会総会学術集会, Feb. 2023.
7.	Koichi Okamoto, Fumika Nakamura, 八木麻衣, 岡田明子, 藤井祥平, Takanori Yoshimoto, 横山怜子, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndrome に合併した大腸腺腫の臨床病理学的特徴., 第98回大腸癌研究会学術集会, Jan. 2023.
8.	Kaizo Kagemoto, Fumika Nakamura, Koichi Okamoto, Takanori Yoshimoto, Tomoyuki Kawaguchi, 横山怜子, Yoshifumi Kida, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama : 鋸歯状ポリポーシス症候群における大腸腫瘍の病理像と発癌機序についての解析., 第60回癌治療学会学術集会, Oct. 2022.
9.	Fumika Nakamura, Koichi Okamoto, kaizo kagemoto, 平田圭市郎, takanori yoshimoto, 横山怜子, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Kumiko Tanaka, Shinji Kitamura, Yasushi Sato and Tetsuji Takayama : Serrated polyposis syndromeにおける発癌リスクとその予防., 第29回日本がん予防学会総会, Jul. 2022.
10.	Koichi Okamoto, Fumika Nakamura and Tetsuji Takayama : Serrated polyposis syndromeに合併した左側及び右側大腸癌の臨床病理学的特徴ならびに発癌機序の解析, 第108回日本消化器病学会総会, Apr. 2022.
11.	Hironori Tanaka, Tetsu Tomonari, kaizo kagemoto, Yasuyuki Okada, hironori wada, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 免疫チェックポイント阻害薬投与中の肝障害., 第59回日本癌治療学会学術集会, Oct. 2021.
12.	矢野庄悟, Fumika Nakamura, Yasushi Sato, akira fukuya, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 消化管悪性腫瘍における免疫チェックポイント阻害薬の効果と免疫関連副作用の関連性について., 第17回日本消化管学会総会学術集会, Feb. 2021.
13.	Fumika Nakamura, Koichi Okamoto, 影本開三, Yoshifumi Kida, Kumiko Tanaka, Shinji Kitamura, Yasushi Sato, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndrome に合併した大腸癌の臨床病理学的特徴ならびに発癌機序の検討., 第17回日本消化管学会総会学術集会, Feb. 2021.
14.	Fumika Nakamura, Kaizo Kagemoto and Tetsuji Takayama : Serrated polyposis syndromeにおける癌の発症リスクと発癌機序の検討., 第28回消化器関連学会週間(JDDW2020), Nov. 2020.
15.	横山怜子, Fumika Nakamura, Yasushi Sato, Kazuhiro Kishi, 和田浩典, Tetsu Tomonari, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : 胃癌におけるICI治療の効果予測因子としてのirAEの意義とその後治療への影響., 第58回日本癌治療学会学術集会, Oct. 2020.
16.	藤井祥平, Fumika Nakamura, Yasushi Sato, 岸和弘, Sumiko Yoshida, Yasuhiro Mitsui, Yasuteru Fujino, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : <第23回若手奨励賞>胃癌における免疫チェックポイント阻害薬の効果と免疫関連副作用(irAE)との関連性についての検討., Shikoku Acta Medica, Vol.76, No.3-4, 173-178, Aug. 2020. (Summary) Recently, immune checkpoint inhibitors(ICI)have been approved for use in advanced gastric cancer(AGC)based on the positive results of ATTRACTION‐2 trial in Japan. There has been accumulating evidence that the development of immune-related adverse events(irAE)may be associated with a response to ICI therapy, particularly in lung cancer, although little is known about these correlations in gastrointestinal cancer. To investigate the efficacy and irAE of ICI treatment and their correlation in AGC, we retrospectively examined 29 patients with AGC who received nivolumab therapy in our departments. Among them, 15 patients(52%)developed irAEs including 4 patients(14%)for grade 3 irAEs ; liver dysfunction(n＝2), type 1 diabetes mellitus(n＝2) and adrenal insufficiency(n＝1). The median overall survival was12．0months in the irAE group and 3．25 months in the non-irAE group(p＝0．164), which suggested the relationship between the effects and irAEs in ICI treatment of AGC. Further research is required to understand the implications of irAE characteristics on ICI response in GCA patients. (Keyword) Immune-checkpoint inhibitors / Gastric cancer / Immune-related adverse events / Nivolumab (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050004953486029824 (CiNii: 1050004953486029824)
17.	Takanori Kashihara, Yoshihiko Miyamoto, Shota Fujimoto, 和田浩典, Tomoyuki Kawaguchi, Yoshifumi Kida, Fumika Nakamura, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 大腸腫瘍に発現するepidermal growth factor receptor in colorectal tumors., 第16回日本消化管学会総会学術集会, Feb. 2020.
18.	Fumika Nakamura, Koichi Okamoto, Kaizoh Kagemoto, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndrome の臨床病理学的特徴ならびに発癌機序の検討., 第16回日本消化管学会総会学術集会, Feb. 2020.
19.	Tomoyuki Kawaguchi, Masanori Takehara, Kaizoh Kagemoto, Satoshi Teramae, Fumika Nakamura, Takahiro Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 胸腺を含む5臓器にわたって10個の同時性多発重複癌を呈したLynch症候群の一例 ., 第57回日本癌治療学会学術集会, Oct. 2019.
20.	Hironori Tanaka, Koichi Okamoto, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Fumika Nakamura, Jinsei Miyoshi, Yasuteru Fujino, Takahiro Tanaka, Tetsu Tomonari, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Yasushi Sato and Tetsuji Takayama : Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma., 第17回日本臨床腫瘍学会学術集会, Jul. 2019.
21.	Fumika Nakamura, Yasushi Sato and Tetsuji Takayama : 消化管腫瘍における免疫チェックポイント阻害薬の自己免疫疾患関連副作用(irAE)の経験, 第26回日本消化器関連学会週間(統合プログラム), Nov. 2018.
22.	Kazuhide Iwasa, Naoki Igata, Tetsuya Honda, Taro Mizutani, Junji Nishioka, Masahiro Sogabe, Toshiya Okahisa, 大櫛聖子, Yoshi Kida, 岡田泰行, 宮本佳彦, Kumiko Tanaka, Fumika Nakamura, 宮城愛, Miwako Kagawa, Shinji Kitamura, Shinji Kitamura, Koichi Okamoto and Tetsuji Takayama : 潰瘍性大腸炎での内視鏡画像解析による大腸粘膜の炎症評価., 第56回日本人工臓器学会大会, Nov. 2018.
23.	和田浩典, Shinji Kitamura, Fumika Nakamura, Akira Fukuya, Masanori Takehara, Yasuyuki Okada, Yasuhiro Mitsui, Jinsei Miyoshi, Yasuteru Fujino, Kumiko Tanaka, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : CRT後咽頭狭窄を伴う表在型食道癌に対して細径内視鏡を用いたPDTが有効であった一例., 第56回日本癌治療学会学術集会, Oct. 2018.
24.	Satoshi Teramae, Kumiko Tanaka, 三橋威志, Yasuhiro Mitsui, Fumika Nakamura, Yasuteru Fujino, Jinsei Miyoshi, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 新規APC遺伝子変異(C.1626+1G>A)を認めた家族性大腸腺腫症の一例., 第6回日本家族性大腸腺腫症研究会学術集会, Sep. 2018.
25.	Masanori Takehara, Yasushi Sato, 津保友香, Akira Fukuya, 岡田泰行, 宮本佳彦, Yasuhiro Mitsui, Yasuteru Fujino, Fumika Nakamura, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : 膵癌と脂肪細胞の相互作用はSAA1の発現を誘導することにより膵癌の浸潤を促進させる., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
26.	津保友香, Yasuhiro Mitsui, Akira Fukuya, Masanori Takehara, 岡田泰行, Jinsei Miyoshi, Yasuteru Fujino, Fumika Nakamura, Kumiko Tanaka, Shinji Kitamura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 切除不能進行神経内分泌癌に対するIrinotecan+Cisplatin併用療法の後方視的検討., 第16回日本臨床腫瘍学会学術集会, Jul. 2018.
27.	Fumika Nakamura, Koichi Okamoto, Kaizoh Kagemoto, Noriaki Murayama, Kumiko Tanaka, Yasuteru Fujino, Shinji Kitamura, 三宮勝隆, Yasushi Sato, Hiroshi Miyamoto, Naoki Muguruma and Tetsuji Takayama : Serrated polyposis syndromeにおける遺伝性及び発癌機序の検討., 第14回日本消化管学会総会学術集会, Feb. 2018.
28.	岡田泰行, Tetsuo Kimura, Koichi Okamoto, Fumika Nakamura, Yasuteru Fujino, Kumiko Tanaka, Jinsei Miyoshi, Yasuhiro Mitsui, Shinji Kitamura, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 抗EGFR抗体薬治療におけるEarly tumor shrinkage(ETS)とEGFR内在化の関連について, 第88回大腸癌研究会, Jan. 2018.
29.	高岡慶史, 影本開三, Yasuhiro Mitsui, Kumiko Tanaka, Fumika Nakamura, Yasuteru Fujino, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Masako Kimura, 仁木美也子, Hiroshi Miyamoto, Naoki Muguruma, 石川正志 and Tetsuji Takayama : 免疫チェックポイント阻害薬で加療した直腸肛門部悪性黒色腫の4例., 第55回日本癌治療学会学術集会, Oct. 2017.
30.	Yasuteru Fujino, Kumiko Tanaka, Fumika Nakamura, Shinji Kitamura, Tetsuo Kimura, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama : 大腸粘膜下層浸潤癌リンパ節転移に関わるmicroRNAの網羅的解析., 第87回大腸癌研究会, Jul. 2017.
31.	Shinji Kitamura, Naoki Muguruma, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 村山典聡, 香川美和子, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, 大塚加奈子, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 内視鏡切除された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第87回日本消化器内視鏡学会総会, May 2014.
32.	宮本佳彦, Naoki Muguruma, Shinji Kitamura, 松本友里, 松本早代, Fumika Nakamura, 髙岡遠, Yasuteru Fujino, Jinsei Miyoshi, Kumiko Tanaka, Takahiro Goji, Hiromi Yano, 香川美和子, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 大腸癌に対する内視鏡分子イメージング技術の開発, 第87回日本消化器内視鏡学会総会, May 2014.
33.	Shinji Kitamura, Naoki Muguruma, 松本友里, 松本早代, 岡崎潤, 髙岡遠, 香川美和子, Yasuteru Fujino, Jinsei Miyoshi, Fumika Nakamura, Kumiko Tanaka, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : バレット食道癌における欧米と日本のマネジメントの相違に関する検討, 第87回日本消化器内視鏡学会総会, May 2014.
34.	藤野泰輝, 大塚加奈子, 田中久美子, Fumika Nakamura, 三好人正, 香川美和子, Takahiro Goji, 髙岡遠, Hiromi Yano, Shinji Kitamura, Hiroshi Miyamoto, Naoki Muguruma, Toshiya Okahisa and Tetsuji Takayama : Sessile serrated adenoma/polyp(SSA/P)の前病変としてのAberrant crypt foci(ACF)の解析, 第10回日本消化管学会総会学術集会, Feb. 2014.
35.	松本早代, Naoki Muguruma, 松本友里, 岡崎潤, 田中久美子, Fumika Nakamura, 藤野泰輝, 三好人正, 香川美和子, Takahiro Goji, 髙岡遠, 村山典聡, Hiromi Yano, Shinji Kitamura, Hiroshi Miyamoto, Toshiya Okahisa and Tetsuji Takayama : 内視鏡治療された直腸カルチノイド(NET-G1)の臨床経過に関する検討, 第80回大腸癌研究会, Jan. 2014.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

家族性大腸腺腫症の十二指腸腺腫に対するConnectivity Map解析に基づいた予防薬の開発 (Project/Area Number: 23K15011 )
Elucidation of carcinogenic mechanism for serrated polyposis syndrome (Project/Area Number: 19K08471 )
Search by Researcher Number (70793743)

Designated Assistant Professor : Nakamura, Fumika

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)